ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
0.00%
Bitcoin
67,823.93
0.15%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) News

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateTimeSourceHeadlineSymbolCompany
05/30/20246:59AMGlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
05/20/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
05/15/202412:45PMGlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
05/08/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
05/02/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
04/03/20246:58AMGlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/14/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/20/20243:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/20/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/08/20246:59AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/02/20242:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/02/20242:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/31/202411:00AMPR Newswire (US)WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/31/202410:15AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/30/20248:45AMPR Newswire (US)WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/30/20248:00AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/29/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/22/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/22/20246:59AMGlobeNewswire Inc.60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/16/20241:56PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
01/16/20246:59AMGlobeNewswire Inc.60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/26/20236:59AMGlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
11/15/20236:29AMGlobeNewswire Inc.60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
10/19/20237:31AMGlobeNewswire Inc.60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
10/12/20233:16PMGlobeNewswire Inc.60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/18/20233:16PMGlobeNewswire Inc.60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/06/20236:31AMGlobeNewswire Inc.60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/30/20236:32AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/22/20236:31AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/15/20236:31AMGlobeNewswire Inc.60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP

Your Recent History

TG
C9X
Consol Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved